According to Korea Biomedical Review, Korean pharmaceutical company Huons has licensed Zephirus busesonide/salmeterol, a dry powder formulation delivered using the Axahaler capsule-based inhaler, from Belgian pharmaceutical company Laboratoires SMB.
Korea Biomedical Review reported that Huons CEO Um Key-an commented, “Respiratory disease is a disease that greatly affects the quality of life. Under Huons’ corporate vision of providing a medical solution for human health, our company has entered into an exclusive licensing agreement with SMB to market Zephirus, expanding the selection of respiratory disease treatments for patients.”
Read the Korea Biomedical Review article.
